Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nykode Therapeutics ASFRA:5VB -0.38%48 Equity-to-Asset is 0.93 as of Mar. 2026, which is 12% above its 10-year median of 0.83. GuruFocus rates FRA:5VB with a GF Score™ of 48/100 and a GF Value™ of €0.70 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,415 Biotechnology companies, Nykode Therapeutics AS ranks better than 89.61% on this metric.
Nykode Therapeutics AS (FRA:5VB) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Nykode Therapeutics AS Equity-to-Asset Related Terms
Nykode Therapeutics AS Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Nykode Therapeutics AS's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5VB vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Nykode Therapeutics AS's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nykode Therapeutics AS Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Nykode Therapeutics AS's Equity-to-Asset falls into.
Nykode Therapeutics AS Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Nykode Therapeutics AS's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nykode Therapeutics AS (FRA:5VB) has a Equity-to-Asset of 0.93 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Nykode Therapeutics AS and its competitors. This is 12% above median its historical median of 0.83. Over the past decade, Nykode Therapeutics AS's Equity-to-Asset has ranged from 0.71 to 0.95. According to the industry distribution chart, Nykode Therapeutics AS ranks #147 out of 1415 companies in the Biotechnology industry, placing it in the top 10.4%.
Is Nykode Therapeutics AS's Equity-to-Asset too high?
Nykode Therapeutics AS's current Equity-to-Asset of 0.93 is 12% above median its 10-year median of 0.83. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 0.95. The Biotechnology industry median Equity-to-Asset is 0.68. Nykode Therapeutics AS's value of 0.93 is 36.8% above this industry median. Based on the distribution chart, Nykode Therapeutics AS ranks #147 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nykode Therapeutics AS has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nykode Therapeutics AS ranks #147 out of 1415 companies for Equity-to-Asset. This places Nykode Therapeutics AS in the top 10% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Nykode Therapeutics AS's value of 0.93 is 36.8% above this benchmark. Historically, Nykode Therapeutics AS's own Equity-to-Asset has ranged from 0.71 to 0.95 over the past decade. While the company's 10-year median is 0.83 vs. the industry median of 0.68, Nykode Therapeutics AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nykode Therapeutics AS's current Equity-to-Asset of 0.93 is 36.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Nykode Therapeutics AS and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nykode Therapeutics AS's current Equity-to-Asset is 0.93, which is 12% above median its own 10-year median of 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (FRA:5VB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.70, compared to a current price of €0.26 — trading 62.9% below its estimated fair value. The current Equity-to-Asset is 0.93, which is 12% above median its 10-year median of 0.83 and 36.8% above the Biotechnology industry median of 0.68. Nykode Therapeutics AS's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Nykode Therapeutics AS (FRA:5VB), the current Equity-to-Asset is 0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nykode Therapeutics AS (FRA:5VB) Overvalued in 2026?
Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued.
The current stock price of €0.26 is trading 62.9% below its estimated GF Value™ of €0.70.
GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.
Key valuation signals for FRA:5VB:
Equity-to-Asset: 0.93 (12% above median its 10-year median of 0.83)
GF Value™: €0.70 vs. price of €0.26 (62.9% below fair value)
Industry Position: 36.8% above the Biotechnology median (#147 of 1415)
No single metric tells the full story. See the FRA:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
48GF Score
Get the complete analysis for FRA:5VB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VB has been successfully added to your 
